Pexelizumab

Pexelizumab
Monoclonal antibody
Type Single-chain variable fragment
Source Humanized (from mouse)
Target Complement component 5
Clinical data
Legal status
  • investigational
Identifiers
ATC code None
ChemSpider none
UNII CHZ6OLQ3UU YesY
  (verify)

Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting[1] and angioplasty,[2][3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]

Current Status

Alexion, the developer of pexelizumab stopped development due to disappointing phase 3 results indicating the heart-attack drug is no better than placebo.[5]

References

  1. ClinicalTrials.gov: Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass
  2. ClinicalTrials.gov: Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction
  3. Testa, L; Van Gaal, WJ; Bhindi, R; Biondi-Zoccai, GG; Abbate, A; Agostoni, P; Porto, I; Andreotti, F; et al. (2008). "Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients". The Journal of thoracic and cardiovascular surgery 136 (4): 884–93. doi:10.1016/j.jtcvs.2007.12.062. PMID 18954626.
  4. Mathew, JP; Shernan, SK; White, WD; Fitch, JC; Chen, JC; Bell, L; Newman, MF (2004). "Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.". Stroke; a journal of cerebral circulation 35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID 15331798.
  5. Analysis: Alexion's pexelizumab fails


This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.